Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model

Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that 219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spi...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2019

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22372

Acceso en línea:

https://doi.org/10.1155/2019/3832513
https://repository.urosario.edu.co/handle/10336/22372

Palabra clave:

Adjuvant
Immune protection inducing protein structure vaccine
Malaria vaccine
Plasmodium falciparum protein
Protozoal protein
Unclassified drug
Animal cell
Animal experiment
Article
Controlled study
Drug formulation
Drug safety
Drug synthesis
Erythrocyte
Female
Humoral immunity
Immunization
Immunogenicity
Immunological tolerance
In vitro study
In vivo study
Malaria falciparum
Male
Merozoite
Mouse
Nonhuman
Plasmodium falciparum
Protein structure
Repeated drug dose
Single drug dose
Vaccine immunogenicity

Rights

License

Abierto (Texto Completo)